The evidence for symptomatic treatments in amyotrophic lateral sclerosis

Current Opinion in Neurology

Volumn 27, Issue 5, 2014, Pages 524-531

  Jenkins, Thomas M ^a   Hollinger, Hannah ^a   McDermott, Christopher J ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Amyotrophic lateral sclerosis; Motor neuron disease; Symptomatic; Treatment

Indexed keywords

VITAMIN D;

AMYOTROPHIC LATERAL SCLEROSIS; ANALGESIA; BODILY SECRETIONS; COGNITION; COMMUNICATION DISORDER; DEEP VEIN THROMBOSIS; DEPRESSION; DYSPHAGIA; FATIGUE; GASTROSTOMY; HUMAN; MENTAL INSTABILITY; NONINVASIVE VENTILATION; NUTRITION; PAIN; PALLIATIVE THERAPY; QUALITY OF LIFE; RESPIRATORY FAILURE; REVIEW; SLEEP; SLEEP DISORDER; SPASTICITY; SURVIVAL; TERMINAL CARE; DISEASE MANAGEMENT; PATHOPHYSIOLOGY; PSYCHOLOGY;

AMYOTROPHIC LATERAL SCLEROSIS; DISEASE MANAGEMENT; HUMANS; QUALITY OF LIFE;

EID: 84925872035     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000135     Document Type: Review

References (92)

1. Aridegbe T, Kandler R, Walters SJ, et al. The natural history of motor neuron disease: assessing the impact of specialist care. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:13-19. An important retrospective observational study that reported a survival benefit of 8 months in favour of specialist multidisciplinary care versus care in the general neurology clinic. This is the longest survival advantage reported for any intervention in ALS to date, but confirmation in RCTs is awaited.
2. Traynor BJ, Alexander M, Corr B, et al. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000. J Neurol Neurosurg Psychiatry 2003;74:1258-1261.
3. Chio A, Bottacchi E, Buffa C, et al. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry 2006;77:948-950.
4. Zoccolella S, Beghi E, Palagano G, et al. ALS multidisciplinary clinic and survival. Results from a population-based study in Southern Italy. J Neurol 2007;254:1107-1112.
5. Van Den Berg JP, Kalmijn S, Lindeman E, et al. Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology 2005;65:1264-1267.
6. Ng L, Khan F, Mathers S. Multidisciplinary care for adults with amyotrophic lateral sclerosisormotor neuron disease. Cochrane Database Syst Rev 2009;4:CD007425.
7. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330:585-591.
8. Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996;347:1425-1431.
9. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012;3:CD001447.
10. Cudkowicz M, Bozik ME, Ingersoll EW, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med 2011;17:1652-1656.
11. Cudkowicz ME, Van Den Berg LH, Shefner JM, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol 2013;12:1059-1067. The results of this phase III RCT of a putative mitochondrial modulator were unfortunately negative despite promising data in animal models. Sadly, this is a common pattern in the field of ALS therapeutics.
12. Pastula DM, Moore DH, Bedlack RS. Creatine for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2012;12:CD005225.
13. Kaufmann P, Thompson JL, Levy G, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol 2009;66:235-244.
14. Orrell RW, Lane RJ, Ross M. Antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2007;1:CD002829.
15. Karam C, Barrett MJ, Imperato T, et al. Vitamin D deficiency and its supplementation in patients with amyotrophic lateral sclerosis. J Clin Neurosci 2013;20:1550-1553. A highly topical issue, this preliminary article was the first to try vitamin D supplementation in ALS patients, showing tentative benefits. An RCT is now needed.
16. Camu W, Tremblier B, Plassot C, et al. Vitamin D confers protection to motoneurons and is a prognostic factor of amyotrophic lateral sclerosis. Neurobiol Aging 2014;35:1198-1205.
17. Gianforcaro A, Hamadeh MJ. Vitamin D as a potential therapy in amyotrophic lateral sclerosis. CNS Neurosci Ther 2014;20:101-111.
18. Bourke SC, Tomlinson M, Williams TL, et al. Effects of noninvasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 2006;5:140-147.
19. Radunovic A, Annane D, Rafiq MK, et al. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2013;3:CD004427. A recent review of the evidence for this important advance in ALS care.
20. Siirala W, Saaresranta T, Vuori A, et al. Using respiratory rate and thoracic movement to assess respiratory insufficiency in amyotrophic lateral sclerosis: a preliminary study. BMC Palliat Care 2012;11:26.
21. NICE. The use of noninvasive ventilation in the management of motor neurone disease. NICE Clinical Guideline 2010;105.
22. Rafiq MK, Bradburn M, Proctor AR, et al. Using transcutaneous carbon dioxide monitor (TOSCA 500) to detect respiratory failure in patients with amyotrophic lateral sclerosis: a validation study. Amyotroph Lateral Scler 2012;13:528-532.
23. Rafiq MK, Proctor AR, McDermott CJ, et al. Respiratory management ofmotor neurone disease: a review of current practice and new developments. Pract Neurol 2012;12:166-176.
24. O'Neill CL, Williams TL, Peel ET, et al. Noninvasive ventilation in motor neuron disease: an update of current UK practice. J Neurol Neurosurg Psychiatry 2012;83:371-376.
25. Baxter SK, Baird WO, Thompson S, et al. The impact on the family carer of motor neurone disease and intervention with noninvasive ventilation. J Palliat Med 2013;16:1602-1609.
26. Spataro R, Bono V, Marchese S, et al. Tracheostomy mechanical ventilation in patients with amyotrophic lateral sclerosis: clinical features and survival analysis. J Neurol Sci 2012;323:66-70.
27. Heritier Barras AC, Adler D, Iancu Ferfoglia R, et al. Is tracheostomy still an option in amyotrophic lateral sclerosis? Reflections of a multidisciplinary work group. Swiss Med Wkly 2013;143:w13830.
28. Prabhakar A, Owen CP, Kaye AD. Anesthetic management of the patient with amyotrophic lateral sclerosis. J Anesth 2013;27:909-918.
29. Onders RP, Elmo M, Kaplan C, et al. Final analysis of the pilot trial of diaphragm pacing in amyotrophic lateral sclerosis with long-term follow-up: diaphragm pacing positively affects diaphragm respiration. Am J Surg 2014;207:393-397. The first pilot trial of diaphragmatic pacing in ALS, an exciting new development, the role of which remains to be determined.
30. Gonzalez-Bermejo J, Morelot-Panzini C, Salachas F, et al. Diaphragm pacing improves sleep in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2012;13:44-54.
31. Mahajan KR, Bach JR, Saporito L, et al. Diaphragm pacing and noninvasive respiratory management of amyotrophic lateral sclerosis/motor neuron disease. Muscle Nerve 2012;46:851-855.
32. McDermott CJ, Maguire C, Cooper CL, et al. Protocol for diaphragm pacing in patients with respiratory muscle weakness due to motor neurone disease (DiPALS): a randomised controlled trial. BMC Neurol 2012;12:74.
33. Young CA, Ellis C, Johnson J, et al. Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. Cochrane Database Syst Rev 2011;5:CD006981.
34. Hobson EV, McGeachan A, Al-Chalabi A, et al. Management of sialorrhoea in motor neuron disease: a survey of current UK practice. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:521-527.
35. Mandler RN, Anderson FA Jr, Miller RG, et al. The ALS Patient Care Database: insights into end-of-life care in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2:203-208.
36. Lipp A, Trottenberg T, Schink T, et al. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003;61:1279-1281.
37. Jackson CE, Gronseth G, Rosenfeld J, et al. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve 2009;39:137-143.
38. Kasarskis EJ, Hodskins J, St Clair WH. Unilateral parotid electron beam radiotherapy as palliative treatment for sialorrhea in amyotrophic lateral sclerosis. J Neurol Sci 2011;308:155-157.
39. Chatwin M, Ross E, Hart N, et al. Cough augmentation with mechanical insufflation/exsufflation in patients with neuromuscular weakness. Eur Respir J 2003;21:502-508.
40. Mustfa N, Aiello M, Lyall RA, et al. Cough augmentation in amyotrophic lateral sclerosis. Neurology 2003;61:1285-1287.
41. Vitacca M, Paneroni M, Trainini D, et al. At home and on demand mechanical cough assistance program for patients with amyotrophic lateral sclerosis. Am J Phys Med Rehabil 2010;89:401-406.
42. Piquet MA. Nutritional approach for patients with amyotrophic lateral sclerosis. Rev Neurol (Paris) 2006;162 Spec No 2:4S177-4S187.
43. Desport JC, Preux PM, Truong TC, et al. Nutritional status is a prognostic factor for survival in ALS patients. Neurology 1999;53:1059-1063.
44. Korner S, Hendricks M, Kollewe K, et al. Weight loss, dysphagia and supplement intake in patients with amyotrophic lateral sclerosis (ALS): impact on quality of life and therapeutic options. BMC Neurol 2013;13:84. This recent study reported that weight loss was associated with worse survival and quality of life in ALS patients; whether improving nutrition influences these parameters remains to be determined and is an important area for further research.
45. Katzberg HD, Benatar M. Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2011;1:CD004030.
46. Stavroulakis T, Baird WO, Baxter SK, et al. Factors influencing decisionmaking in relation to timing of gastrostomy insertion in patients with motor neurone disease. BMJ Support Palliat Care 2014;4:57-63.
47. Stavroulakis T, Walsh T, Shaw PJ, et al. Gastrostomy use in motor neurone disease (MND): a review, meta-analysis and survey of current practice. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:96-104. Optimal management of malnutrition, and in particular the role of gastrostomy, is an important unmet need in ALS. This study surveys current gastrostomy practice and insertion techniques, and reports preliminary evidence that radiologically guided insertion may be safer; RCTs are needed.
48. Muscaritoli M, Kushta I, Molfino A, et al. Nutritional and metabolic support in patients with amyotrophic lateral sclerosis. Nutrition 2012;28:959-966.
49. Chio A, Finocchiaro E, Meineri P, et al. Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. ALS Percutaneous Endoscopic Gastrostomy Study Group. Neurology 1999;53:1123-1125.
50. Zamietra K, Lehman EB, Felgoise SH, et al. Noninvasive ventilation and gastrostomy may not impact overall quality of life in patients with ALS. Amyotroph Lateral Scler 2012;13:55-58.
51. Mazzini L, Corra T, Zaccala M, et al. Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. J Neurol 1995;242:695-698.
52. Chio A, Mora G, Leone M, et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 2002;59:99-103.
53. Restivo DA, Casabona A, Nicotra A, et al. ALS dysphagia pathophysiology: differential botulinum toxin response. Neurology 2013;80:616-620. An interesting study outlining a possible alternative to gastrostomy in patients with upper motor neuron bulbar symptoms; careful patient selection appears crucial.
54. Korner S, Siniawski M, Kollewe K, et al. Speech therapy and communication device: impact on quality of life and mood in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2013;14:20-25.
55. Yamagishi J, Veaux C, King S, et al. Speech synthesis technologies for individuals with vocal disabilities: voice banking and reconstruction. Acoust Sci Tech 2012;33:1-5.
56. Veaux C, Yamagishi J, King S. Towards personalized synthesized voices for individuals with vocal disabilities: voice banking and reconstruction. SLPAT 2013;107-111.
57. Saz O, Hain T. Asynchronous factorisation of speaker and background with feature transforms in speech recognition. Interspeech 2013;1238-1242.
58. Shefner JM, Watson ML, Meng L, et al. A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:574-581. A phase IIa trial of a troponin activator, showing some promise as a symptomatic treatment for weakness. The phase IIb trial will be reported soon.
59. Drory VE, Goltsman E, Reznik JG, et al. The value of muscle exercise in patients with amyotrophic lateral sclerosis. J Neurol Sci 2001;191:133-137.
60. Norris FH Jr, U KS, Sachais B, Carey M. Trial of baclofen in amyotrophic lateral sclerosis. Arch Neurol 1979;36:715-716.
61. Ashworth NL, Satkunam LE, Deforge D. Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2012;2:CD004156.
62. Bethoux F, Boulis N, McClelland S 3rd, et al. Use of intrathecal baclofen for treatment of severe spasticity in selected patients with motor neuron disease. Neurorehabil Neural Repair 2013;27:828-833.
63. Miller RG, Moore DH 2nd, Gelinas DF, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001;56:843-848.
64. Baldinger R, Katzberg HD, Weber M. Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2012;4:CD004157.
65. Brettschneider J, Kurent J, Ludolph A. Drug therapy for pain in amyotrophic lateral sclerosis ormotor neuron disease. Cochrane Database Syst Rev 2013;6:CD005226. A recent review outlining the existing lack of evidence for treatment of this common symptom.
66. Lomen-Hoerth C, Murphy J, Langmore S, et al. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003;60:1094-1097.
67. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72:257-268.
68. De Jesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72:245-256.
69. Bak TH, Chandran S. What wires together dies together: verbs, actions and neurodegeneration in motor neuron disease. Cortex 2012;48:936-944.
70. Elamin M, Phukan J, Bede P, et al. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology 2011;76:1263-1269.
71. Mioshi E, Lillo P, Kiernan M, et al. Activities of daily living in motor neuron disease: role of behavioural and motor changes. J Clin Neurosci 2012;19:552-556.
72. Chio A, Vignola A, Mastro E, et al. Neurobehavioral symptoms in ALS are negatively related to caregivers' burden and quality of life. Eur J Neurol 2010;17:1298-1303.
73. Abrahams S, Newton J, Niven E, et al. Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:9-14. This study describes the Edinburgh Cognitive Assessment Score (ECAS), a rapid validated screening tool to identify cognitive impairment in ALS patients, historically an underappreciated area, but now recognized to be an important and prevalent problem.
74. Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 2004;63:1364-1370.
75. Pioro EP, Brooks BR, Cummings J, et al. Dextromethorphan plus ultra lowdose quinidine reduces pseudobulbar affect. Ann Neurol 2010;68:693-702.
76. Patatanian E, Casselman J. Dextromethorphan/quinidine for the treatment of pseudobulbar affect. Consult Pharm 2014;29:264-269. A meta-analysis reporting evidence in favour of this new treatment for emotional lability, although long-term efficacy and safety data are lacking.
77. Bello-Haas VD, Florence JM, Kloos AD, et al. A randomized controlled trial of resistance exercise in individuals with ALS. Neurology 2007;68:2003-2007.
78. Dal Bello-Haas V, Florence JM. Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev 2013;5:CD005229. Patients often ask about exercise in clinic, and exercise has been proposed in both pathogenesis and treatment of ALS. This is a recent review of evidence for exercise as a therapeutic intervention; more evidence is required.
79. Carter GT, Weiss MD, Lou JS, et al. Modafinil to treat fatigue in amyotrophic lateral sclerosis: an open label pilot study. Am J Hosp Palliat Care 2005;22:55-59.
80. Rabkin JG, Gordon PH, McElhiney M, et al. Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study. Muscle Nerve 2009;39:297-303.
81. Payne C, Wiffen PJ, Martin S. Interventions for fatigue and weight loss in adults with advanced progressive illness. CochraneDatabase Syst Rev 2012;1:CD008427.
82. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999;341:793-800.
83. Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874-879.
84. Sachdeva A, Dalton M, Amaragiri SV, et al. Elastic compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev 2010;7:CD001484.
85. Mahan CE, Fisher MD, Mills RM, et al. Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population. Thromb Res 2013;132:520-526.
86. Collaboration CT, Dennis M, Sandercock PA, et al. Effectiveness of thighlength graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet 2009;373:1958-1965.
87. Greig MF, Rochow SB, Crilly MA, et al. Routine pharmacological venous thromboembolism prophylaxis in frail older hospitalised patients: where is the evidence? Age Ageing 2013;42:428-434.
88. Gladman M, Dehaan M, Pinto H, et al. Venous thromboembolisminamyotrophic lateral sclerosis: a prospective study. Neurology 2014;82:1674-1677. This isfirst studyto focusonvenous thromboembolismin the ALS patient group; the authors estimate high incidence from a prospectively followed cohort of 50 patients. Further study is required before treatment recommendations can be made.
89. Blackhall LJ. Amyotrophic lateral sclerosis and palliative care: where we are, and the road ahead. Muscle Nerve 2012;45:311-318.
90. Clemens KE, Klaschik E. Morphine in the management of dyspnoea in ALS. A pilot study. Eur J Neurol 2008;15:445-450.
91. Simon ST, Niemand AM, Benalia H, et al. Acceptability and preferences of six different routes of drug application for acute breathlessness: a comparison study between the United Kingdom and Germany. J Palliat Med 2012;15:1374-1381.
92. Aoun SM, Connors SL, Priddis L, et al. Motor neurone disease family carers' experiences of caring, palliative care and bereavement: an exploratory qualitative study. Palliat Med 2012;26:842-850.